Orchestra BioMed Secures FDA Breakthrough Device Designation for AVIM Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Source: Newsfilter
- FDA Breakthrough Designation: Orchestra BioMed has received a second Breakthrough Device Designation from the FDA for AVIM Therapy, covering over 7.7 million adults with uncontrolled hypertension despite medication, marking a significant advancement in cardiovascular treatment.
- Clinical Trial Support: This designation aligns with the ongoing BACKBEAT global pivotal trial aimed at evaluating the safety and efficacy of AVIM Therapy in hypertensive patients, further strengthening the strategic partnership with Medtronic.
- Reimbursement Pathway Optimization: The Breakthrough Device Designation supports favorable reimbursement pathways, including New Technology Add-on Payment (NTAP) and Transitional Pass-Through (TPT) payments, which will facilitate timely patient access and provider adoption.
- Significant Market Potential: As a bioelectronic treatment designed to substantially lower blood pressure in hypertensive patients, AVIM Therapy is expected to generate multi-billion-dollar market opportunities for Orchestra BioMed, further solidifying its leadership position in the medical device market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 77.960
Low
102.00
Averages
111.76
High
120.00
Current: 77.960
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Long-Term Investment Opportunities Amid Market Uncertainty
- UPS's Transformation Progress: Despite challenges from Amazon's open delivery network, UPS is shifting towards higher-margin customers, achieving revenue per package growth, and is expected to reach a business inflection point in the second half of 2026, indicating strong long-term investment potential.
- Hormel's Brand Revamp: After a 60% drop in stock price, Hormel Foods is reworking its brand and product portfolio, with recent organic growth trending upward, and its 5.6% dividend yield providing stable returns for long-term investors, showcasing resilience during tough times.
- Medtronic's Focus Strategy: Medtronic is enhancing profitability by spinning off its diabetes business and launching new products like the Hugo surgical robot; despite a 40% stock price decline, its 3.6% dividend yield remains attractive to long-term investors, underscoring its leadership in the medical device sector.
- Importance of Dividends: UPS, Hormel, and Medtronic all offer stable dividends, helping investors maintain confidence during market volatility, and while the market may not fully recognize these companies' business improvements, their long-term outlook remains optimistic.
See More
Long-Term Investment Potential of UPS, Hormel, and Medtronic
- UPS Transformation Progress: Despite competition from Amazon, UPS is shifting towards higher-margin customers and expects to achieve a business turnaround by the second half of 2026, with revenue per package growth indicating management's successful strategy, while a 6.5% dividend yield attracts long-term investors.
- Hormel Brand Restructuring: Hormel Foods is reworking its brand and product portfolio after a 60% stock price decline, with recent organic growth trends improving; its 5.6% dividend yield and 46% controlling stake provide flexibility for long-term decision-making.
- Medtronic Profitability Focus: Medtronic is enhancing profitability by spinning off its diabetes business, which is expected to positively impact earnings; despite a 40% decline from its 2021 high, its 3.6% dividend yield remains appealing to long-term investors.
- Importance of Dividends: UPS, Hormel, and Medtronic offer stable dividends in an uncertain market, helping investors maintain confidence during volatility, while also making significant progress in their business overhauls.
See More
Medtronic Shares Decline, Investors Should Take Note
- Stock Decline: Medtronic (MDT) shares have fallen 40% from their 2021 peak, currently priced at $76.03, reflecting market pessimism about its future performance, prompting investors to assess risks carefully.
- Business Restructuring: The company is readjusting its product portfolio to focus on higher-margin businesses, planning to spin off its lower-margin diabetes division, MiniMed, which is expected to enhance overall profit margins and positively impact earnings.
- New Product Launch: Medtronic is introducing the Hugo surgical robot to fill a market gap, leveraging its strong customer relationships in the healthcare sector, which is anticipated to receive a positive market response and drive future growth.
- Dividend Yield: With a dividend yield of 3.73% and a history of 48 consecutive years of dividend increases, Medtronic, despite recent modest hikes, is positioned for potential faster dividend growth in the future, attracting long-term investor interest.
See More
Medtronic Faces Challenges but Holds Great Potential
- Stock Price Decline: Medtronic's shares have fallen 40% from their 2021 peak, reflecting market concerns over its profitability and growth outlook, although the current dividend yield of 3.6% offers an attractive proposition for investors.
- Portfolio Restructuring: The company is readjusting its product portfolio to focus on higher-margin businesses, planning to spin off its lower-margin diabetes division, MiniMed, which is expected to enhance overall margins and immediately boost earnings.
- New Product Launch: Medtronic is introducing the Hugo surgical robot, which is anticipated to be well-received in the market, especially given its strong customer relationships in the healthcare sector, aiding future growth prospects.
- Dividend Growth History: Medtronic has increased its dividend for 48 consecutive years, and while recent hikes have been modest, this track record demonstrates the company's resilience during tough times, with expectations for a return to faster dividend growth in the future.
See More
Top Healthcare Stocks for Retirees
- Pfizer's Challenges and Opportunities: As an industry-leading pharmaceutical company, Pfizer faces challenges from multiple patent expirations, yet offers a high dividend yield of 6.5%; however, with a payout ratio exceeding 100%, it may be more suitable for aggressive investors.
- Medtronic's Transformation Journey: Medtronic boasts a 48-year streak of annual dividend increases with a current yield of 3.6%, as the company is restructuring by cutting costs and focusing on profitable divisions, which is expected to restore growth and enhance market valuation.
- Omega's Stable Returns: Omega Healthcare Investors focuses on senior housing properties and, despite facing difficulties during the pandemic, has maintained its dividend; with a current yield of 5.8%, the company is gradually recovering and is ideal for investors seeking stable income.
- Retiree Investment Choices: For retirees, Pfizer, Medtronic, and Omega Healthcare represent compelling high-yield healthcare stocks to consider, each offering distinct business models that can provide stable cash flow and potential long-term growth for investment portfolios.
See More
Investment Opportunities in Healthcare Stocks
- Pfizer's Challenges and Opportunities: As an industry-leading pharmaceutical company, Pfizer faces challenges from multiple patent expirations; however, with a current dividend yield of 6.5% and a payout ratio exceeding 100%, it is more suited for aggressive investors, while the company remains committed to long-term growth.
- Medtronic's Transformation Journey: Medtronic boasts a 48-year history of annual dividend increases, currently offering a 3.6% yield, as the company is restructuring by cutting costs and focusing on its most profitable divisions, with expectations to return to growth and achieve higher market valuations post-transition.
- Omega Healthcare's Stable Returns: Omega Healthcare, focusing on senior housing properties, has a 5.8% dividend yield and, despite challenges during the pandemic, has begun to recover its business, positioning itself to benefit from the growing demand of an aging population in the long term.
- Choices for Retired Investors: For retirees, Pfizer, Medtronic, and Omega Healthcare represent high-yield healthcare stocks worth considering; although they operate under different business models, they all provide stable cash flow and potential for long-term growth in an investment portfolio.
See More
Long-Term Investment Opportunities Amid Market Uncertainty
- UPS's Transformation Progress: Despite challenges from Amazon's open delivery network, UPS is shifting towards higher-margin customers, achieving revenue per package growth, and is expected to reach a business inflection point in the second half of 2026, indicating strong long-term investment potential.
- Hormel's Brand Revamp: After a 60% drop in stock price, Hormel Foods is reworking its brand and product portfolio, with recent organic growth trending upward, and its 5.6% dividend yield providing stable returns for long-term investors, showcasing resilience during tough times.
- Medtronic's Focus Strategy: Medtronic is enhancing profitability by spinning off its diabetes business and launching new products like the Hugo surgical robot; despite a 40% stock price decline, its 3.6% dividend yield remains attractive to long-term investors, underscoring its leadership in the medical device sector.
- Importance of Dividends: UPS, Hormel, and Medtronic all offer stable dividends, helping investors maintain confidence during market volatility, and while the market may not fully recognize these companies' business improvements, their long-term outlook remains optimistic.
See More
Long-Term Investment Potential of UPS, Hormel, and Medtronic
- UPS Transformation Progress: Despite competition from Amazon, UPS is shifting towards higher-margin customers and expects to achieve a business turnaround by the second half of 2026, with revenue per package growth indicating management's successful strategy, while a 6.5% dividend yield attracts long-term investors.
- Hormel Brand Restructuring: Hormel Foods is reworking its brand and product portfolio after a 60% stock price decline, with recent organic growth trends improving; its 5.6% dividend yield and 46% controlling stake provide flexibility for long-term decision-making.
- Medtronic Profitability Focus: Medtronic is enhancing profitability by spinning off its diabetes business, which is expected to positively impact earnings; despite a 40% decline from its 2021 high, its 3.6% dividend yield remains appealing to long-term investors.
- Importance of Dividends: UPS, Hormel, and Medtronic offer stable dividends in an uncertain market, helping investors maintain confidence during volatility, while also making significant progress in their business overhauls.
See More
Medtronic Shares Decline, Investors Should Take Note
- Stock Decline: Medtronic (MDT) shares have fallen 40% from their 2021 peak, currently priced at $76.03, reflecting market pessimism about its future performance, prompting investors to assess risks carefully.
- Business Restructuring: The company is readjusting its product portfolio to focus on higher-margin businesses, planning to spin off its lower-margin diabetes division, MiniMed, which is expected to enhance overall profit margins and positively impact earnings.
- New Product Launch: Medtronic is introducing the Hugo surgical robot to fill a market gap, leveraging its strong customer relationships in the healthcare sector, which is anticipated to receive a positive market response and drive future growth.
- Dividend Yield: With a dividend yield of 3.73% and a history of 48 consecutive years of dividend increases, Medtronic, despite recent modest hikes, is positioned for potential faster dividend growth in the future, attracting long-term investor interest.
See More
Medtronic Faces Challenges but Holds Great Potential
- Stock Price Decline: Medtronic's shares have fallen 40% from their 2021 peak, reflecting market concerns over its profitability and growth outlook, although the current dividend yield of 3.6% offers an attractive proposition for investors.
- Portfolio Restructuring: The company is readjusting its product portfolio to focus on higher-margin businesses, planning to spin off its lower-margin diabetes division, MiniMed, which is expected to enhance overall margins and immediately boost earnings.
- New Product Launch: Medtronic is introducing the Hugo surgical robot, which is anticipated to be well-received in the market, especially given its strong customer relationships in the healthcare sector, aiding future growth prospects.
- Dividend Growth History: Medtronic has increased its dividend for 48 consecutive years, and while recent hikes have been modest, this track record demonstrates the company's resilience during tough times, with expectations for a return to faster dividend growth in the future.
See More
Top Healthcare Stocks for Retirees
- Pfizer's Challenges and Opportunities: As an industry-leading pharmaceutical company, Pfizer faces challenges from multiple patent expirations, yet offers a high dividend yield of 6.5%; however, with a payout ratio exceeding 100%, it may be more suitable for aggressive investors.
- Medtronic's Transformation Journey: Medtronic boasts a 48-year streak of annual dividend increases with a current yield of 3.6%, as the company is restructuring by cutting costs and focusing on profitable divisions, which is expected to restore growth and enhance market valuation.
- Omega's Stable Returns: Omega Healthcare Investors focuses on senior housing properties and, despite facing difficulties during the pandemic, has maintained its dividend; with a current yield of 5.8%, the company is gradually recovering and is ideal for investors seeking stable income.
- Retiree Investment Choices: For retirees, Pfizer, Medtronic, and Omega Healthcare represent compelling high-yield healthcare stocks to consider, each offering distinct business models that can provide stable cash flow and potential long-term growth for investment portfolios.
See More
Investment Opportunities in Healthcare Stocks
- Pfizer's Challenges and Opportunities: As an industry-leading pharmaceutical company, Pfizer faces challenges from multiple patent expirations; however, with a current dividend yield of 6.5% and a payout ratio exceeding 100%, it is more suited for aggressive investors, while the company remains committed to long-term growth.
- Medtronic's Transformation Journey: Medtronic boasts a 48-year history of annual dividend increases, currently offering a 3.6% yield, as the company is restructuring by cutting costs and focusing on its most profitable divisions, with expectations to return to growth and achieve higher market valuations post-transition.
- Omega Healthcare's Stable Returns: Omega Healthcare, focusing on senior housing properties, has a 5.8% dividend yield and, despite challenges during the pandemic, has begun to recover its business, positioning itself to benefit from the growing demand of an aging population in the long term.
- Choices for Retired Investors: For retirees, Pfizer, Medtronic, and Omega Healthcare represent high-yield healthcare stocks worth considering; although they operate under different business models, they all provide stable cash flow and potential for long-term growth in an investment portfolio.
See More
